Management of Cutaneous Melanoma

Author

David M. Miller

Published

August 21, 2020

Pearls for the management of cutaneous melanoma

TABLE OF CONTENTS

Overview & Learning Objectives
Clinical Cases

Case 1
Case 2
Case 3
Case 4

Timeline of FDA Approved Therapies for Melanoma

Overview & Learning Objectives

Clinical Cases

CASE 1
Synopsis

Pathology reveals:

  • HISTOLOGIC TYPE: Superficial spreading melanoma
  • PRECURSOR LESION: Not identified
  • MAXIMUM TUMOR THICKNESS: 3.0 mm
  • ANATOMIC LEVEL: At least level IV
  • ULCERATION: Present
  • MITOTIC RATE: 9 per mm2
  • LYMPHOVASCULAR INVASION: Present, Foci suspicious for lymphovascular invasion
  • METHOD OF DETECTION: Hematoxylin and eosin
  • RADIAL GROWTH PHASE: Present
  • VERTICAL GROWTH PHASE: Present
  • TYPE OF VERTICAL GROWTH: Epithelioid
  • MICROSATELLITES: Cannot be assessed
  • PERINEURAL INVASION: Cannot be assessed
  • TUMOR-INFILTRATING LYMPHOCYTES: Present, nonbrisk
  • TUMOR REGRESSION: Absent
  • MARGINS: Extending to inked lateral and deep resection margins

Case 1 Clinical Questions:

  • What is this patient’s T stage?
  • What would be your next steps in work up?
    • What would be your surgical plan?
    • What additional studies (if any) would you order?



CASE 2
Synopsis

Relevant Work Up To Date:

  • Tumor:
    • 3.2 mm thick, ulcerated SSM with 5 mitoses, Right mid back
  • Nodal:
    • 1/14 nodes positive for melanoma on sentinel lymph node biopsy
  • Imaging:
    • No evidence of distant disease
  • Molecular Testing:
    • BRAF p.V600E (c.1799T>A): absent
    • BRAF p.V600K (c.1798_1799delGTinsAA): present
      • INTERPRETATION: POSITIVE for variant in BRAF.

Case 2 Clinical Questions:

  • What is this patient’s pathological stage?
  • What are the therapeutic options for this patient?



CASE 3
Synopsis

Case 3 Clinical Questions:

  • What are your next steps in management?
  • If regionally metastatic melanoma is confirmed, what management options are available?



CASE 4
Synopsis

Case 4 Clinical Questions:

  • What therapeutic strategies are available for this patient?
  • Given the patient’s comorbidities, what would be your first-line treatment strategy?



Timeline of FDA-Approved Medications for Melanoma





Interactive Timeline of FDA-Approved Therapies for Melanoma

Hydroxyurea (DROXIA) \n Setting: Metastatic
Dacarbazine (DTIC-DOME®) Setting: Metastatic
Interferon alfa-2b (INTRON® A) Setting: Adjuvant
Aldesleukin (PROLEUKIN®) Setting: Metastatic
Ipilimumab (YERVOY®) Setting: Metastatic
Pegylated Inteferon-alfa-2b (SYLATRON™) Setting: Adjuvant
Vemurafenib (ZELBORAF®) Setting: Metastatic
Trametinib (MEKINIST®) Setting: Metastatic
Dabrafenib (TAFINLAR®) Setting: Metastatic
Trametinib (MEKINIST®) In Combination With Dabrafenib (TAFINLAR®) Setting: Metastatic
Pembrolizumab (KEYTRUDA®) Setting: Metastatic
Nivolumab (OPDIVO®) Setting: Metastatic
Nivolumab (OPDIVO®) In Combination With Ipilimumab (YERVOY®) Setting: Metastatic
Talimogene laherparepvec (IMLYGIC™) Setting: Unresectable
Ipilimumab (YERVOY®) Setting: Adjuvant
Cobimetinib (COTELLIC®) In Combination with Vemurafenib (ZELBORAF®) Setting: Metastatic
Dabrafenib (TAFINLAR®) In Combination with Trametinib (MEKINIST®) Setting: Metastatic
Nivolumab (OPDIVO®) Setting: Adjuvant
Dabrafenib (TAFINLAR®) In Combination With Trametinib (MEKINIST®) Setting: Adjuvant
Encorafenib (BRAFTOVI™) in combination with Binimetinib Setting: Metastatic
Pembrolizumab (KEYTRUDA®) Setting: Adjuvant
Atezolizumab (TECENTRIQ®) in Combination with Vemurafenib/Cobimetinib \n Setting: Metastatic
0
0
1900
1950
2000
2050
2100

















This site represents our opinions only. See our full Disclaimer and Terms of Use Agreement